This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Girard, M. Articles by Weinhold, K. Search for Related Content PubMed PubMed Citation Articles by Girard, M. Articles by Weinhold, K.

 Previous Article  |  Next Article 

J. Virol., 10 1995, 6239-6248, Vol 69, No. 10
Copyright © 1995, American Society for Microbiology

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

M Girard, B Meignier, F Barre-Sinoussi, MP Kieny, T Matthews, E Muchmore, PL Nara, Q Wei, L Rimsky and K Weinhold
Institut Pasteur, Paris, France.

The extraordinary genetic diversity of human immunodeficiency virus type 1 (HIV-1) is a major problem to overcome in the development of an effective vaccine. In the most reliable animal model of HIV-1 infection, chimpanzees were immunized with various combinations of HIV- 1 antigens, which were derived primarily from the surface glycoprotein, gp160, of HIV-1 strains LAI and MN. The immunogens also included a live recombinant canarypox virus expressing a gp160-MN protein. In one experiment, two chimpanzees were immunized multiple times; one animal received antigens derived only from HIV-1LAI, and the second animal received antigens from both HIV-1LAI and HIV-1MN. In another experiment, four chimpanzees were immunized in parallel a total of five times over 18 months; two animals received purified gp160 and V3-MN peptides, whereas the other two animals received the recombinant canarypox virus and gp160. At 3 months after the final booster, all immunized and naive control chimpanzees were challenged by intravenous inoculation of HIV-1SF2; therefore, the study represented an intrasubtype B heterologous virus challenge. Virologic and serologic follow-up showed that the controls and the two chimpanzees immunized with the live recombinant canarypox virus became infected, whereas the other animals that were immunized with gp160 and V3-MN peptides were protected from infection. Evaluation of both cellular and humoral HIV- specific immune responses at the time of infectious HIV-1 challenge identified the following as possible correlates of protection: antibody titers to the V3 loop of MN and neutralizing antibody titers to HIV-1MN or HIV-1LAI, but not to HIV-1SF2. The results of this study indicate that vaccine-mediated protection against intravenous infection with heterologous HIV-1 strains of the same subtype is possible with some immunogens.

This article has been cited by other articles:

• Dickover, R., Garratty, E., Yusim, K., Miller, C., Korber, B., Bryson, Y. (2006). Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.. J. Virol. 80: 6525-6533 [Abstract] [Full Text]  
• Kanekiyo, M., Matsuo, K., Hamatake, M., Hamano, T., Ohsu, T., Matsumoto, S., Yamada, T., Yamazaki, S., Hasegawa, A., Yamamoto, N., Honda, M. (2005). Mycobacterial Codon Optimization Enhances Antigen Expression and Virus-Specific Immune Responses in Recombinant Mycobacterium bovis Bacille Calmette-Guerin Expressing Human Immunodeficiency Virus Type 1 Gag. J. Virol. 79: 8716-8723 [Abstract] [Full Text]  
• Mooij, P., Nieuwenhuis, I. G., Knoop, C. J., Doms, R. W., Bogers, W. M. J. M., ten Haaft, P. J. F., Niphuis, H., Koornstra, W., Bieler, K., Kostler, J., Morein, B., Cafaro, A., Ensoli, B., Wagner, R., Heeney, J. L. (2004). Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. J. Virol. 78: 3333-3342 [Abstract] [Full Text]  
• Verrier, F., Burda, S., Belshe, R., Duliege, A.-M., Excler, J.-L., Klein, M., Zolla-Pazner, S. (2000). A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates. J. Virol. 74: 10025-10033 [Abstract] [Full Text]  
• von Mehren, M., Arlen, P., Tsang, K. Y., Rogatko, A., Meropol, N., Cooper, H. S., Davey, M., McLaughlin, S., Schlom, J., Weiner, L. M. (2000). Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas. Clin. Cancer Res. 6: 2219-2228 [Abstract] [Full Text]  
• Robert-Guroff, M., Kaur, H., Patterson, L. J., Leno, M., Conley, A. J., McKenna, P. M., Markham, P. D., Richardson, E., Aldrich, K., Arora, K., Murty, L., Carter, L., Zolla-Pazner, S., Sinangil, F. (1998). Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus. J. Virol. 72: 10275-10280 [Abstract] [Full Text]  
• Mwaengo, D. M., Novembre, F. J. (1998). Molecular Cloning and Characterization of Viruses Isolated from Chimpanzees with Pathogenic Human Immunodeficiency Virus Type 1 Infections. J. Virol. 72: 8976-8987 [Abstract] [Full Text]  
• Heeney, J. L., Teeuwsen, V. J. P., van Gils, M., Bogers, W. M. J. M., Morghen, C. D. G., Radaelli, A., Barnett, S., Morein, B., Akerblom, L., Wang, Y., Lehner, T., Davis, D. (1998). beta -Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl. Acad. Sci. USA 95: 10803-10808 [Abstract] [Full Text]  
• Letvin, N. L. (1998). Progress in the Development of an HIV-1 Vaccine. Science 280: 1875-1880 [Abstract] [Full Text]  
• Wei, Q., Fultz, P. N. (1998). Extensive Diversification of Human Immunodeficiency Virus Type 1 Subtype B Strains during Dual Infection of a Chimpanzee That Progressed to AIDS. J. Virol. 72: 3005-3017 [Abstract] [Full Text]  
• Stott, E., Almond, N, Kent, K, Walker, B, Hull, R, Rose, J, Silvera, P, Sangster, R, Corcoran, T, Lines, J, Silvera, K, Luciw, P, Murphy-Corb, M, Momin, P, Bruck, C (1998). Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus- HIV-1 chimeric virus. J. Gen. Virol. 79: 423-432 [Abstract]  
• Richardson, J., Moraillon, A., Crespeau, F., Baud, S., Sonigo, P., Pancino, G. (1998). Delayed Infection after Immunization with a Peptide from the Transmembrane Glycoprotein of the Feline Immunodeficiency Virus. J. Virol. 72: 2406-2415 [Abstract] [Full Text]  
• Zolla-Pazner, S., Lubeck, M., Xu, S., Burda, S., Natuk, R. J., Sinangil, F., Steimer, K., Gallo, R. C., Eichberg, J. W., Matthews, T., Robert-Guroff, M. (1998). Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees. J. Virol. 72: 1052-1059 [Abstract] [Full Text]  
• Connor, R. I., Korber, B. T. M., Graham, B. S., Hahn, B. H., Ho, D. D., Walker, B. D., Neumann, A. U., Vermund, S. H., Mestecky, J., Jackson, S., Fenamore, E., Cao, Y., Gao, F., Kalams, S., Kunstman, K. J., McDonald, D., McWilliams, N., Trkola, A., Moore, J. P., Wolinsky, S. M. (1998). Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. J. Virol. 72: 1552-1576 [Abstract] [Full Text]  
• Smith, A. D., Geisler, S. C., Chen, A. A., Resnick, D. A., Roy, B. M., Lewi, P. J., Arnold, E., Arnold, G. F. (1998). Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1. J. Virol. 72: 651-659 [Abstract] [Full Text]  
• Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., Lusso, P. (1995). Identification of RANTES, MIP-1alpha, and MIP-1beta as the Major HIV-Suppressive Factors Produced by CD8+ T Cells. Science 270: 1811-1815 [Abstract]